Please wait while the formulary information is being retrieved.
DANTROLENE SODIUM (DANTROLENE SODIUM)
- Malignant hyperthermia
- Muscle spasticity of cerebral origin
- Muscle spasticity of spinal origin
- Malignant hyperthermia prevention
- Muscle spasm
dantrolene 100 mg capsule
- 1 capsule (100 mg) by oral route 3 times per day
dantrolene 25 mg capsule
- 1 capsule (25 mg) by oral route 2 times per day
dantrolene 50 mg capsule
- 1 capsule (50 mg) by oral route 3 times per day
25 mg capsule
- 1 capsule (25 mg) by oral route 2 times per day
50 mg capsule
- 1 capsule (50 mg) by oral route 3 times per day
Malignant hyperthermia
- 4 mg/kg by oral route 3 times per day for 1 day
- 4 mg/kg by oral route 3 times per day for 2 days
- 4 mg/kg by oral route 4 times per day for 1 day
- 4 mg/kg by oral route 4 times per day for 2 days
- 8 mg/kg by oral route 3 times per day for 1 day
- 8 mg/kg by oral route 3 times per day for 2 days
- 8 mg/kg by oral route 4 times per day for 1 day
- 8 mg/kg by oral route 4 times per day for 2 days
Malignant hyperthermia prevention
- 1 mg/kg by oral route 4 times per day for 1 day before surgery
- 1 mg/kg by oral route 4 times per day for 2 days before surgery
- 1 mg/kg by oral route 4 times per day before surgery
- 1.3 mg/kg by oral route 3 times per day for 1 day before surgery
- 1.3 mg/kg by oral route 3 times per day for 2 days before surgery
- 1.3 mg/kg by oral route 3 times per day before surgery
- 2 mg/kg by oral route 4 times per day for 1 day before surgery
- 2 mg/kg by oral route 4 times per day for 2 days before surgery
- 2 mg/kg by oral route 4 times per day before surgery
- 2.67 mg/kg by oral route 3 times per day for 1 day before surgery
- 2.67 mg/kg by oral route 3 times per day for 2 days before surgery
- 2.67 mg/kg by oral route 3 times per day before surgery
Muscle spasm
- 1 capsule (25 mg) by oral route once daily
- 1 capsule (25 mg) by oral route 2 times per day
- 1 capsule (25 mg) by oral route 3 times per day
- 1 capsule (25 mg) by oral route 4 times per day
- 2 capsules (50 mg) by oral route 2 times per day
- 2 capsules (50 mg) by oral route 3 times per day
- 2 capsules (50 mg) by oral route 4 times per day
- None
Contraindicated
- Adalat Cc
- Afeditab Cr
- aliskiren-amlodipin-hcthiazide
- aliskiren-amlodipine
- amlodipine
- amlodipine-atorvastatin
- amlodipine-benazepril
- amlodipine-olmesartan
- amlodipine-valsartan
- amlodipine-valsartan-hcthiazid
- Amturnide
- Azor
- Caduet
- Calan
- Calan Sr
- Cardene Iv
- Cardene Iv In Dextrose
- Cardene Iv In Sodium Chloride
- Cardene Sr
- Cardizem
- Cardizem Cd
- Cardizem La
- Cartia Xt
- Dilacor Xr
- Dilt-xr
- diltiazem HCl
- Exforge
- Exforge Hct
- felodipine
- isradipine
- Lotrel
- Matzim La
- nicardipine
- nicardipine in dextrose,iso-os
- nicardipine in NaCl (iso-os)
- Nifedical Xl
- nifedipine
- nimodipine
- nisoldipine
- Norvasc
- Nymalize
- olmesartan-amlodipin-hcthiazid
- Procardia
- Procardia Xl
- Sular
- Tarka
- Taztia Xt
- Tekamlo
- telmisartan-amlodipine
- Tiazac
- trandolapril-verapamil
- Tribenzor
- Twynsta
- verapamil
- Verelan
- Verelan Pm
Severe
Moderate
- None
- Hepatitis
Contraindicated
- Disease of liver
Severe
Moderate
- Chronic obstructive pulmonary disease
- Pulmonary disease
- Severe cardiac disease
DANTROLENE SODIUM (DANTROLENE SODIUM)
- Malignant hyperthermia
- Muscle spasticity of cerebral origin
- Muscle spasticity of spinal origin
- Malignant hyperthermia prevention
- Muscle spasm
- None
- Dizziness
- Drowsy
- Fatigue
- Malaise
- Muscle weakness
More Frequent
Severe
Less Severe
- Acute confusion
- Allergic dermatitis
- Depression
- Drug-induced hepatitis
- Dysuria
- Hematuria
- Pleural effusions
- Pruritus of skin
- Respiratory depression
- Seizure disorder
- Skin rash
- Urticaria
- Abdominal pain with cramps
- Anorexia
- Chills
- Constipation
- Diarrhea
- Diplopia
- Dysgeusia
- Dysphagia
- Fever
- Headache disorder
- Increased urinary frequency
- Insomnia
- Nausea
- Nervousness
- Urinary incontinence
- Visual changes
- Vomiting
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal hepatic function tests
- Anaphylaxis
- Anemia
- Aplastic anemia
- Eosinophilia
- Extravasation injury
- Gastrointestinal hemorrhage
- Heart failure
- Jaundice
- Leukopenia
- Malignant lymphoma
- Pericarditis
- Severe diarrhea
- Thrombocytopenic disorder
- Thrombophlebitis
Less Severe
- Abnormal blood pressure
- Acneiform eruption
- Back pain
- Crystalluria
- Erectile dysfunction
- Eye tearing
- Hirsutism
- Hyperhidrosis
- Myalgias
- Tachycardia
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Dantrolene (oral)
No long term safety data. Weigh risk-benefit.
- 1 Day – 5 Years
- No long term safety data. Weigh risk-benefit.
Dantrolene (oral)
- Severity Level:
C
- Additional Notes: Insufficient human and animal data
Contraindicated
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Precaution Exists
Dantrolene
Insuff data avail; low levels excreted in milk; potential for infant adv eff
General | Excretion Potential | Effect on Infant | Notes |
Evaluate use carefully | Excreted | Not known; no or inclusive data | Insuff data avail; low levels excreted in milk; potential for infant adv eff |
No Known Risk
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- Infrequently, dantrolene may cause very serious (possibly fatal) liver problems. The risk is greater if you use high doses of dantrolene (over 400-800 milligrams per day), or are female, older than 35 years, or taking other medications. Signs of liver problems usually appear between 3-12 months of treatment.<br /><br />To reduce your risk of this side effect, you should have regular liver tests checked by your doctor. Tell your doctor right away if you develop any of the following symptoms of liver disease: persistent nausea/vomiting, stomach/abdominal pain, dark urine, yellowing eyes/skin, unusual tiredness. To further reduce your risk of side effects, do not increase your dose or take it more often or for longer than prescribed.<br /><br /> The lowest effective dose should be used. The manufacturer recommends that if your condition does not improve after 45 days of treatment, your doctor must be notified and dantrolene should be stopped.
Malignant hyperthermia | |
T88.3 | Malignant hyperthermia due to anesthesia |
T88.3xxA | Malignant hyperthermia due to anesthesia, initial encounter |
Muscle spasm | |
M62.83 | Muscle spasm |
M62.830 | Muscle spasm of back |
M62.831 | Muscle spasm of calf |
M62.838 | Other muscle spasm |
R25.2 | Cramp and spasm |
Muscle spasticity of cerebral origin | |
M62.83 | Muscle spasm |
M62.830 | Muscle spasm of back |
M62.831 | Muscle spasm of calf |
M62.838 | Other muscle spasm |
R25.2 | Cramp and spasm |
Muscle spasticity of spinal origin | |
M62.83 | Muscle spasm |
M62.830 | Muscle spasm of back |
M62.831 | Muscle spasm of calf |
M62.838 | Other muscle spasm |
R25.2 | Cramp and spasm |
0-9 | A-Z |
---|---|
M62.83 | Muscle spasm |
M62.83 | Muscle spasm |
M62.83 | Muscle spasm |
M62.830 | Muscle spasm of back |
M62.830 | Muscle spasm of back |
M62.830 | Muscle spasm of back |
M62.831 | Muscle spasm of calf |
M62.831 | Muscle spasm of calf |
M62.831 | Muscle spasm of calf |
M62.838 | Other muscle spasm |
M62.838 | Other muscle spasm |
M62.838 | Other muscle spasm |
R25.2 | Cramp and spasm |
R25.2 | Cramp and spasm |
R25.2 | Cramp and spasm |
T88.3 | Malignant hyperthermia due to anesthesia |
T88.3xxA | Malignant hyperthermia due to anesthesia, initial encounter |
Formulary Reference Tool